View
88
Download
2
Category
Preview:
DESCRIPTION
Duration of Dual Antiplatelet Therapy. European and US Guidelines. PCI-CURE CV Death or MI. CHARISMA Instantaneous Hazard for Moderate or Severe Bleeding. CHARISMA Primary End Point. TRILOGY-ACS Primary Efficacy End Point to 30 Months (Age < 75 years). DAPT Trial Total Enrollment . - PowerPoint PPT Presentation
Citation preview
Duration of Dual Antiplatelet Therapy
European and US Guidelines
PCI-CURECV Death or MI
CHARISMAInstantaneous Hazard for Moderate or Severe
Bleeding
CHARISMA Primary End Point
TRILOGY-ACS Primary Efficacy End Point to 30 Months (Age < 75
years)
DAPT TrialTotal Enrollment
DES vs BMS
DAPT Trials Unanswered Questions
OPTIMIZESecond-generation DES
Effect of Short- and Long-term DAPT
New Trials With Ticagrelor
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
References
References (cont)
References (cont)
References (cont)
Recommended